The global medical cannabis market exhibited strong growth during 2015-2020. Cannabis is a psychoactive drug that is derived from the cannabis plant of the Cannabaceae family. It was used medicinally in ancient Indian, Chinese, Egyptian and Islamic cultures. Nowadays, cannabis finds application in the treatment of a wide range of diseases and symptoms, including cancer, chronic pain, depression, arthritis, diabetes, glaucoma, migraines, epilepsy, multiple sclerosis, acquired immunodeficiency syndrome (AIDS), amyotrophic lateral sclerosis (ALS), Alzheimer’s, post-traumatic stress disorder (PTSD), Parkinson’s and Tourette’s. Owing to its therapeutic benefits, cannabis has been approved for medical use in numerous countries, with varying degrees of legal restrictions. Some of these countries include Argentina, Brazil, Canada, Chile, Colombia, Czech Republic, Germany, Italy, Mexico, Spain, the United Kingdom, the United States and Uruguay. Looking forward, IMARC Group expects the global medical cannabis market to grow at a CAGR of 15.3% during 2021-2026.
Global Medical Cannabis Market Drivers:
IMARC Group provides an analysis of the key trends in each sub-segment of the global medical cannabis market report, along with forecasts for growth at the global, regional and country-level from 2021-2026. Our report has categorized the market based on region, species, derivatives, application, end-use, and route of administration.
Breakup by Species:
On the basis of species, the market has been segmented as cannabis Indica, Sativa and hybrid. Currently, Cannabis Indica dominates the market, holding the largest share. It is often used in the treatment of insomnia, relaxing the muscles, relieving body pains, headaches and migraines.
Breakup by Derivatives:
Based on derivatives, the market has been divided into cannabidiol (CBD), tetrahydrocannabinol (THC) and others. CBD is majorly used for medical purposes due to its non-psychotic effect and low levels of toxicity, whereas THC is utilized to reduce the side-effects of AIDS and cancer treatment.
Breakup by Application:
The market has also been divided on the basis of application; wherein cancer represents the leading category. Other major applications of cannabis include arthritis, migraine, epilepsy and others.
Breakup by End-Use:
On the basis of end-use, the market has been segregated into the pharmaceutical industry, research and development centers, and others. Currently, the pharmaceutical industry represents the biggest end user.
Breakup by Route of Administration:
Based on the route of administration, the market has been categorized into oral solutions and capsules, smoking, vaporizers, topicals and others. Oral solutions and capsules represent the biggest segment, accounting for the largest market share.
On the geographical front, North America (the United States and Canada) enjoys the leading position in the market. The recent legalization of cannabis in North America for both recreational and medical purposes has been a major driver of the market growth. Other key regions include Europe (Germany, Italy, France, the Netherlands and Spain), Asia Pacific, Latin America, and Middle East and Africa.
The report has also examined the competitive landscape of the market. Some of the major players include:
Key Questions Answered in This Report:
The global medical cannabis market was worth around US$ 16.5 Billion in 2019.
According to the estimates by IMARC Group, the global medical cannabis market will exhibit strong growth during the next five years.
The growing prevalence of chronic diseases, along with the increasing utilization of medical cannabis for treating different conditions, represents one of the key factors impelling the market growth.
Legalizing cannabis for medicinal purposes in various countries represents one of the major trends in the market.
Lockdowns imposed by governments of several countries to contain the spread of the coronavirus disease (COVID-19) have led to a decline in medical tourism and supply chain disruptions around the world. As a result, the medical cannabis market is currently experiencing negative growth.
On the basis of species, the market has been classified into Indica, Sativa and hybrid.
Based on the derivative, the market has been divided into cannabidiol (CBD), tetrahydrocannabinol (THC) and others.
The market has been categorized on the basis of the application into cancer, arthritis, migraine, epilepsy and others.
On the basis of end use, the market has been segmented into the pharmaceutical industry, research and development centers, and others.
Based on the route of administration, the market has been segregated into oral solutions and capsules, smoking, vaporizers, topicals, and others.
Region-wise, the market has been classified into North America (the United States and Canada), Europe (Germany, Italy, France, the Netherlands and Spain), Latin America, Asia Pacific, and Middle East and Africa.
Leading players are Canopy Growth Corporation, GW Pharmaceuticals PLC, Aurora Cannabis, Inc., Aphria, Inc., MedReleaf Corporation, Insys Therapeutics, Inc., CanniMed Therapeutics, Inc., Cara Therapeutics, Inc. and UCANN Corporation.
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at